A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing Forms of Multiple Sclerosis

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Multiple Sclerosis
  • Age: Between 18 - 55 Years
  • Gender: Male or Female

Inclusion Criteria

Have primary-progressive MS, secondary-progressive MS or relapsing-remitting MS

Are on a stable dose of MS medication for at least 6 months or have been in stable condition without and an MS immunotherapy or corticosteroid for at least 6 months

Recruitment Status

Closed
Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at inhealth@iu.edu or by phone at (888) 264-0005.